EGFR and head and neck squamous cell carcinoma: For HNSCC, monoclonal antibodies against epidermal growth factor receptor (EGFR) and human EGF receptor 3 (HER3), in addition to as small-molecule inhibitors against serine threonine kinase, cyclin-dependent kinase and tyrosine kinase are under clinical investigation [13,14,15].